These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

392 related items for PubMed ID: 9373453

  • 1. Serum LH concentrations in hypogonadal men during transdermal testosterone replacement through scrotal skin: further evidence that ageing enhances testosterone negative feedback. The Testoderm Study Group.
    Winters SJ, Atkinson L.
    Clin Endocrinol (Oxf); 1997 Sep; 47(3):317-22. PubMed ID: 9373453
    [Abstract] [Full Text] [Related]

  • 2. Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men.
    Meikle AW, Mazer NA, Moellmer JF, Stringham JD, Tolman KG, Sanders SW, Odell WD.
    J Clin Endocrinol Metab; 1992 Mar; 74(3):623-8. PubMed ID: 1740497
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. LH and non-SHBG testosterone and estradiol levels during testosterone replacement of hypogonadal men: further evidence that steroid negative feedback increases as men grow older.
    Winters SJ, Wang C, Fortigel Study Group.
    J Androl; 2010 Mar; 31(3):281-7. PubMed ID: 19959827
    [Abstract] [Full Text] [Related]

  • 5. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men.
    Arver S, Dobs AS, Meikle AW, Caramelli KE, Rajaram L, Sanders SW, Mazer NA.
    Clin Endocrinol (Oxf); 1997 Dec; 47(6):727-37. PubMed ID: 9497881
    [Abstract] [Full Text] [Related]

  • 6. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.
    Behre HM, Baus S, Kliesch S, Keck C, Simoni M, Nieschlag E.
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2394-403. PubMed ID: 7543113
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Long-term substitution therapy of hypogonadal men with transscrotal testosterone over 7-10 years.
    Behre HM, von Eckardstein S, Kliesch S, Nieschlag E.
    Clin Endocrinol (Oxf); 1999 May; 50(5):629-35. PubMed ID: 10468929
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study.
    Wang C, Berman N, Longstreth JA, Chuapoco B, Hull L, Steiner B, Faulkner S, Dudley RE, Swerdloff RS.
    J Clin Endocrinol Metab; 2000 Mar; 85(3):964-9. PubMed ID: 10720024
    [Abstract] [Full Text] [Related]

  • 11. Transdermal testosterone therapy in the treatment of male hypogonadism.
    Ahmed SR, Boucher AE, Manni A, Santen RJ, Bartholomew M, Demers LM.
    J Clin Endocrinol Metab; 1988 Mar; 66(3):546-51. PubMed ID: 3350906
    [Abstract] [Full Text] [Related]

  • 12. Testosterone substitution normalizes elevated serum leptin levels in hypogonadal men.
    Jockenhövel F, Blum WF, Vogel E, Englaro P, Müller-Wieland D, Reinwein D, Rascher W, Krone W.
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2510-3. PubMed ID: 9253326
    [Abstract] [Full Text] [Related]

  • 13. A 5α-reductase (SRD5A2) polymorphism is associated with serum testosterone and sex hormone-binding globulin in men, while aromatase (CYP19A1) polymorphisms are associated with oestradiol and luteinizing hormone reciprocally.
    Yeap BB, Knuiman MW, Handelsman DJ, Ho KKY, Hui J, Divitini ML, Arscott GM, McQuillan B, Hung J, Beilby JP.
    Clin Endocrinol (Oxf); 2019 Feb; 90(2):301-311. PubMed ID: 30353958
    [Abstract] [Full Text] [Related]

  • 14. Treatment of primary hypogonadism in men by the transdermal administration of testosterone.
    Findlay JC, Place V, Snyder PJ.
    J Clin Endocrinol Metab; 1989 Feb; 68(2):369-73. PubMed ID: 2493029
    [Abstract] [Full Text] [Related]

  • 15. Progressive impairment of testicular endocrine function in ageing men: Testosterone and dihydrotestosterone decrease, and luteinizing hormone increases, in men transitioning from the 8th to 9th decades of life.
    Yeap BB, Manning L, Chubb SAP, Handelsman DJ, Almeida OP, Hankey GJ, Flicker L.
    Clin Endocrinol (Oxf); 2018 Jan; 88(1):88-95. PubMed ID: 28945276
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Randomized placebo-controlled trial of testosterone replacement in men with mild Leydig cell insufficiency following cytotoxic chemotherapy.
    Howell SJ, Radford JA, Adams JE, Smets EM, Warburton R, Shalet SM.
    Clin Endocrinol (Oxf); 2001 Sep; 55(3):315-24. PubMed ID: 11589674
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site- -a clinical research center study.
    Meikle AW, Arver S, Dobs AS, Sanders SW, Rajaram L, Mazer NA.
    J Clin Endocrinol Metab; 1996 May; 81(5):1832-40. PubMed ID: 8626843
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.